Clinical Trials Browser

Phase 2 × mocetinostat × Lymphoid × Clear all

NCT00358982 2015-07-03

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 2 Terminated

Hodgkin Disease, Recurrence

NCT00359086 2015-07-01

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Phase 2 Completed

Lymphoma, Recurrence

NCT00431873 2015-07-01

A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

Phase 2 Completed

LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00543582 2015-07-01

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Phase 2 Terminated

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell